IN8bio Announced Updated Clinical Data Showing Improved Survival Data For Phase 1 INB-200 And Phase 2 INB-400 Studies At ASCO Annual Meeting May 29 - June 2

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!